Febrile Seizures & Self-Limited Focal Epilepsies

Febrile seizures are the most common seizure type in childhood, affecting 2–5% of children between 6 months and 5 years of age. They occur in the context of fever without evidence of central nervous system infection and are broadly classified as simple or complex based on duration, focality, and recurrence within a febrile episode. Several childhood-onset focal epilepsies share a self-limited natural history with excellent prognosis—the ILAE 2022 classification formally recognizes self-limited epilepsy with centrotemporal spikes (SeLECTS), self-limited epilepsy with autonomic seizures (formerly Panayiotopoulos syndrome), and childhood occipital visual epilepsy (formerly Gastaut-type) as distinct syndromes within this group. These conditions exemplify age-dependent epileptogenesis, with seizures arising from genetically determined cortical excitability that resolves spontaneously with brain maturation.

Febrile Seizures

Epidemiology and Classification

Febrile seizures are defined as seizures occurring between the ages of 6 months and 5 years in association with a febrile illness not caused by a central nervous system infection, without prior neonatal seizures or a previous unprovoked seizure. They are the most common seizure type in childhood, with a cumulative incidence of 2–5% in North America and Western Europe, and up to 8–14% in some Asian populations. The distinction between simple and complex febrile seizures has important prognostic implications.

Risk Factors for Febrile Seizure Recurrence

Approximately one-third of children with a first febrile seizure will experience at least one recurrence. Risk factors for recurrence include:

• Young age at first febrile seizure (<18 months)
• Lower degree of fever at the time of the initial seizure
• Shorter duration of fever before the seizure
• Family history of febrile seizures (first-degree relative)
• Frequent febrile illnesses (daycare attendance)

Risk of Subsequent Epilepsy

The overall risk of developing epilepsy after febrile seizures is approximately 2–7%, compared with 1% in the general population. Risk factors for developing epilepsy include complex febrile seizures, neurodevelopmental abnormalities, family history of epilepsy, and prolonged febrile seizures or febrile status epilepticus. Prolonged febrile seizures, particularly those with focal features, have been associated with the development of mesial temporal sclerosis and temporal lobe epilepsy, a finding supported by the FEBSTAT study. The genetic epilepsy with febrile seizures plus (GEFS+) spectrum represents a familial syndrome in which febrile seizures persist beyond age 6 or are accompanied by afebrile seizures, most commonly linked to SCN1A and SCN1B pathogenic variants.

Management of Febrile Seizures

Simple febrile seizures are benign and do not require antiseizure medication prophylaxis. The AAP practice guideline emphasizes reassurance, education about seizure first aid, and discussion of the favorable prognosis. Antipyretics do not prevent febrile seizure recurrence. For children with frequent or prolonged febrile seizures, intermittent rectal diazepam or intranasal midazolam at the onset of fever or at the first sign of a seizure is effective in aborting prolonged episodes. Continuous daily antiseizure medication prophylaxis (with phenobarbital or valproate) has been shown to reduce recurrence but is not recommended due to the unfavorable risk-benefit ratio, given the benign nature of most febrile seizures and the side effects of chronic therapy.

Self-Limited Epilepsy With Centrotemporal Spikes (SeLECTS)

Overview and Terminology

SeLECTS, formerly known as benign epilepsy of childhood with centrotemporal spikes (BECTS) or benign rolandic epilepsy, is the most common childhood focal epilepsy, accounting for 15–25% of all childhood epilepsies. The ILAE 2022 classification replaced the term "benign" with "self-limited" to acknowledge that, although seizure remission is expected, some children experience transient cognitive or behavioral difficulties. The typical age of onset is 4–10 years, with a peak between 7 and 10 years, and a slight male predominance.

Clinical Features

The hallmark of SeLECTS is brief focal seizures arising from the perirolandic (central) cortex, most commonly occurring during drowsiness or sleep:

• Perioral and oropharyngeal symptoms: Unilateral clonic movements of the face and mouth, tingling or numbness of the tongue, lips, or inner cheek; drooling (sialorrhea) and dysarthria or anarthria with preserved consciousness
• Motor involvement: Unilateral clonic jerking of the face that may spread to the ipsilateral arm (jacksonian march); rarely progresses to bilateral tonic-clonic seizures, particularly during sleep
• Duration: Typically brief (30 seconds to 2 minutes); seizures during sleep may be longer
• Frequency: Infrequent in most children (fewer than 10 lifetime seizures); some experience clusters

EEG Findings

The interictal EEG is highly characteristic and often more informative than the clinical history:

• Centrotemporal (rolandic) spikes: High-amplitude, biphasic or triphasic sharp waves with a stereotyped morphology, maximal at C3/C4 or C5/C6, with a horizontal dipole (negative temporal, positive frontal)
• Sleep activation: Spike frequency markedly increases during NREM sleep; may become nearly continuous in some children
• Bilateral spikes: Present in approximately 30% of patients; may be independent or synchronous
• Normal background: The background EEG activity is normal, which is an essential feature distinguishing SeLECTS from epileptic encephalopathies

Treatment and Prognosis

The decision to treat SeLECTS with antiseizure medication depends on seizure frequency, severity, and the impact on the child and family. Many children require no treatment, as seizures are infrequent and self-limited. When treatment is initiated, levetiracetam, oxcarbazepine, and carbamazepine are commonly used first-line agents. Sulthiame is widely used in Europe but unavailable in the United States. Treatment is typically discontinued after 1–2 years of seizure freedom or by age 14–16. Remission occurs in virtually all patients before the end of puberty, with EEG normalization following clinical remission.

Self-Limited Epilepsy With Autonomic Seizures (Panayiotopoulos Syndrome)

Clinical Features

Self-limited epilepsy with autonomic seizures, formerly known as Panayiotopoulos syndrome or early-onset benign occipital epilepsy, is a common childhood epilepsy (second only to SeLECTS among self-limited focal epilepsies) with onset typically between ages 3 and 6 years. The defining feature is the prominence of autonomic symptoms during seizures:

• Emetic symptoms: Nausea and vomiting (ictus emeticus) are the most common autonomic manifestation, occurring in approximately 80% of seizures; often the first or only symptom noticed by caregivers
• Other autonomic features: Pallor, flushing, mydriasis, cardiorespiratory changes, incontinence, and thermoregulatory disturbances
• Impaired consciousness: Progressive obtundation or unresponsiveness often follows the autonomic symptoms
• Eye and head deviation: Tonic deviation of the eyes is common; may progress to hemiconvulsions or generalized convulsions
• Prolonged seizures: Unlike SeLECTS, seizures are often prolonged (30 minutes or more in one-third of patients), qualifying as autonomic status epilepticus; despite the prolonged duration, the long-term prognosis remains excellent

EEG Findings

The EEG in Panayiotopoulos syndrome is variable and does not show a single characteristic pattern:

• High-amplitude, focal or multifocal epileptiform discharges that may shift location between recordings
• Occipital predominance is common but not required; centrotemporal, frontal, or diffuse discharges may be seen
• Marked activation during sleep, with increased spike frequency in NREM sleep
• Normal background activity

Prognosis and Management

Panayiotopoulos syndrome has an excellent prognosis with universal seizure remission, typically within 1–2 years of onset, and most children experience only 2–5 total seizures. Treatment with antiseizure medication may not be necessary in many cases. When treatment is considered, carbamazepine, oxcarbazepine, or levetiracetam may be used. A rescue benzodiazepine plan (rectal diazepam or intranasal midazolam) is important given the risk of prolonged seizures (autonomic status epilepticus). The key to management is accurate diagnosis and parental reassurance, as the clinical presentation can mimic gastroenteritis, migraine, or even encephalitis.

Childhood Occipital Visual Epilepsy (Gastaut Type)

Clinical Features

Childhood occipital visual epilepsy, formerly known as late-onset benign occipital epilepsy or Gastaut syndrome, presents later than Panayiotopoulos syndrome, with a peak onset at 8–9 years. The clinical hallmark is brief visual seizures:

• Elementary visual hallucinations: Multicolored circles or spots, typically in one hemifield, lasting seconds to minutes; the most specific feature
• Ictal blindness: Transient visual loss may occur during or after the visual hallucination
• Eye and head deviation: Tonic deviation contralateral to the hemisphere of origin
• Postictal headache: A migrainous headache frequently follows the seizure, which can lead to misdiagnosis as migraine with aura
• Progression: Seizures may evolve to hemiclonic or bilateral tonic-clonic seizures

EEG Findings

The interictal EEG shows occipital spikes or spike-and-wave discharges, which may attenuate or disappear with eye opening (fixation-off sensitivity). Sleep activation is common. The background is normal.

Differential Diagnosis

Treatment and Prognosis

Carbamazepine or oxcarbazepine are often effective first-line treatments. Levetiracetam is an alternative. Most children achieve remission, though a small percentage may experience seizures into adolescence or adulthood, distinguishing Gastaut-type epilepsy from the universally self-limited SeLECTS and Panayiotopoulos syndrome. Treatment duration is typically 2–3 years of seizure freedom before considering discontinuation.

Summary of Self-Limited Focal Epilepsies of Childhood

References

1. Specchio N, Wirrell EC, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1398–1442.
2. Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1349–1397.
3. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512–521.
4. Subcommittee on Febrile Seizures, American Academy of Pediatrics. Neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics 2011;127(2):389–394.
5. Shinnar S, Bello JA, Chan S, et al. MRI abnormalities following febrile status epilepticus in children: the FEBSTAT study. Neurology 2012;79(9):871–877.
6. Panayiotopoulos CP. Benign childhood focal seizures and related epileptic syndromes. In: A Clinical Guide to Epileptic Syndromes and Their Treatment. 2nd ed. Springer; 2010:339–413.
7. Wirrell EC, Nabbout R, Scheffer IE, et al. Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1333–1348.
8. Ferrie CD, Caraballo R, Covanis A, et al. Panayiotopoulos syndrome: a consensus view. Dev Med Child Neurol 2006;48(3):236–240.
9. Caraballo RH, Cersosimo RO, Fejerman N. Childhood occipital epilepsy of Gastaut: a study of 33 patients. Epilepsia 2008;49(2):288–297.
10. Lesca G, Rudolf G, Bruneau N, et al. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet 2013;45(9):1061–1066.
11. Nasiri J, Taghavi SA. Febrile seizures: an updated review. J Pediatr Rev 2021;9(1):59–68.
12. Verrotti A, Matricardi S, Di Giacomo DL, et al. Current pharmacotherapy of childhood occipital epilepsies. Expert Opin Pharmacother 2014;15(8):1079–1090.